Adaptive Biotechnologies Corp Cash Flow Conversion Efficiency
Adaptive Biotechnologies Corp cash flow conversion efficiency. Based on the latest financial reports, Adaptive Biotechnologies Corp (ADPT) has a cash flow conversion efficiency ratio of -0.035x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.13 Million) by net assets ($204.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Adaptive Biotechnologies Corp (2017–2024)
Cash flow conversion efficiency of Adaptive Biotechnologies Corp from 2017 to 2024. This chart illustrates how Adaptive Biotechnologies Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ADPT stock price and chart for real-time trading data and today's change.
Adaptive Biotechnologies Corp Cash Flow Conversion Ratio Explained
Adaptive Biotechnologies Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Adaptive Biotechnologies Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adaptive Biotechnologies Corp ranked by their cash flow conversion efficiency. Also see Adaptive Biotechnologies Corp (ADPT) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alsea S.A.B. de C.V
MX:ALSEA
|
0.054x |
|
KANSAI PAINT SPON.ADR/1/2
F:KAP0
|
N/A |
|
Top Choice Medical Investment Co Inc
SHG:600763
|
0.069x |
|
Seabridge Gold Inc.
TO:SEA
|
-0.002x |
|
Haemonetics Corporation
NYSE:HAE
|
0.089x |
|
Legend Holdings Corporation
F:1PC
|
-0.009x |
|
Hamilton Insurance Group, Ltd.
NYSE:HG
|
0.037x |
|
Cecep Environmental Protection Equipment Co Ltd
SHE:300140
|
0.064x |
Annual Cash Flow Conversion Efficiency for Adaptive Biotechnologies Corp (2017–2024)
The table below shows the annual cash flow conversion efficiency of Adaptive Biotechnologies Corp from 2017 to 2024. Review Adaptive Biotechnologies Corp free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $202.49 Million | $-95.21 Million | -0.470x | +7.27% |
| 2023-12-31 | $308.28 Million | $-156.32 Million | -0.507x | -27.94% |
| 2022-12-31 | $464.10 Million | $-183.94 Million | -0.396x | -24.24% |
| 2021-12-31 | $604.10 Million | $-192.73 Million | -0.319x | -58.42% |
| 2020-12-31 | $743.27 Million | $-149.68 Million | -0.201x | -155.99% |
| 2019-12-31 | $571.04 Million | $205.40 Million | 0.360x | +187.81% |
| 2018-12-31 | $-258.11 Million | $-32.26 Million | 0.125x | -19.47% |
| 2017-12-31 | $-224.62 Million | $-34.86 Million | 0.155x | -- |
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diag… Read more